IN8BIO Inc., a clinical-stage biopharmaceutical company, announced that its INB-200 clinical trial for glioblastoma patients has demonstrated significant clinical progress. A patient in the trial has surpassed four years without progression, marking a notable milestone in the treatment of front-line, grade IV glioblastoma. The company presented these positive results at the ASCO 2025 Annual Meeting, where it was reported that patients receiving multiple doses of INB-200 achieved a median progression-free survival of 16.1 months, notably longer than the 6.9 months typically observed with the standard-of-care Stupp protocol. Additionally, 40% of these patients remained progression-free for over 18 months with no significant toxicities observed. These findings highlight the potential of INB-200 to extend overall survival and provide durable therapy for glioblastoma patients.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。